Checkpoint Therapeutics Reports Acceptance of IND Application for CK-101 (FBIO)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress Biotech (NASDAQ: FBIO) company, announced today that its Investigational New Drug (“IND”) application for CK-101, its novel, oral, third generation EGFR inhibitor product candidate, has been accepted by the U.S. Food and Drug Administration (“FDA”) and is now active. The IND acceptance enables Checkpoint to begin a Phase 1/2 clinical trial of CK-101. The trial, expected to begin in September, is designed to assess the safety, tolerability and efficacy of CK-101 in EGFR T790M mutation-positive non-small cell lung cancer patients.
“The acceptance of this IND marks an important milestone for Checkpoint and the CK-101 program,” said James F. Oliviero, III, President and CEO of Checkpoint Therapeutics. “We look forward to commencing clinical trials for CK-101, which we plan to develop as both a monotherapy and in combination with our portfolio of immuno-oncology agents.”
Checkpoint holds an exclusive worldwide license (except with respect to certain Asian countries) to CK-101 (also known as RX518), which it acquired from NeuPharma, Inc. in 2015.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vail Resorts (MTN) Names New Board Member
- DBV Technologies (DBVT) Announces Topline data from Two-Year OLFUS-VIPES Study; No SAEs Reported
- SAExploration (SAEX) Receives ~$24.4M in Tax Credit Certificates from Alaska's DoR; Can Tap Remaining $15M in Senior Loan Facility
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!